HedgeChatter

  • Home /
  • Tag Archives

BMRN

BioMarin to Present at Two Upcoming Investor Conferences in New York

[GlobeNewswire] – – 2014 Citi Global Healthcare Conference – 2014 RBC Capital Markets’ Global Healthcare Conference moreView todays social media effects on BMRNView the latest stocks trending across Twitter. Click to view dashboardSee who BioMarin is hiring next, click here to view […]

February 19, 2014 Bystocknews , Comments Off on BioMarin to Present at Two Upcoming Investor Conferences in New York read more

4:31 pm Biomarin Pharm confirms FDA approval for VIMIZIM (elosulfase alfa) for the treatment of patients with Morquio A syndrome

moreView todays social media effects on BMRNView the latest stocks trending across Twitter. Click to view dashboardSee who BioMarin is hiring next, click here to view […]

February 18, 2014 Bystocknews , Comments Off on 4:31 pm Biomarin Pharm confirms FDA approval for VIMIZIM (elosulfase alfa) for the treatment of patients with Morquio A syndrome read more

BioMarin to Discuss FDA Approval of VIMIZIM(TM) and Provide Preliminary 2013 Results

[GlobeNewswire] – – Company to Host Conference Call and Webcast, Tuesday, February 18 at 8:00 a.m. ET moreView todays social media effects on BMRNView the latest stocks trending across Twitter. Click to view dashboardSee who BioMarin is hiring next, click here to view […]

February 17, 2014 Bystocknews , Comments Off on BioMarin to Discuss FDA Approval of VIMIZIM(TM) and Provide Preliminary 2013 Results read more

4:31 pm Biomarin Pharm confirms FDA approval for VIMIZIM (elosulfase alfa) for the treatment of patients with Morquio A syndrome

moreView todays social media effects on BMRNView the latest stocks trending across Twitter. Click to view dashboardSee who BioMarin is hiring next, click here to view […]

February 15, 2014 Bystocknews , Comments Off on 4:31 pm Biomarin Pharm confirms FDA approval for VIMIZIM (elosulfase alfa) for the treatment of patients with Morquio A syndrome read more

4:31 pm Biomarin Pharm confirms FDA approval for VIMIZIM (elosulfase alfa) for the treatment of patients with Morquio A syndrome

moreView todays social media effects on BMRNView the latest stocks trending across Twitter. Click to view dashboardSee who BioMarin is hiring next, click here to view […]

February 14, 2014 Bystocknews , Comments Off on 4:31 pm Biomarin Pharm confirms FDA approval for VIMIZIM (elosulfase alfa) for the treatment of patients with Morquio A syndrome read more

BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome

[GlobeNewswire] – SAN RAFAEL, Calif. — BioMarin Pharmaceutical Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VIMIZIM(TM) (elosulfase alfa) for patients with Mucopolysaccharidosis type … moreView todays social media effects on BMRNView the latest stocks trending across Twitter. Click to view dashboardSee who BioMarin is hiring next, click here to view […]

February 14, 2014 Bystocknews , Comments Off on BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome read more

BioMarin Presents 15 Abstracts From Basic Research to Clinical Trials at Lysosomal Disease Network’s 10th Annual WORLDSymposium(TM)

[GlobeNewswire] – 12 Abstracts on MPS diseases and 3 on Pompe Disease 10-Year Naglazyme(R) (galsulfase) Data Suggests Increased Survival of MPS VI Patients moreView todays social media effects on BMRNView the latest stocks trending across Twitter. Click to view dashboardSee who BioMarin is hiring next, click here to view […]

February 13, 2014 Bystocknews , Comments Off on BioMarin Presents 15 Abstracts From Basic Research to Clinical Trials at Lysosomal Disease Network’s 10th Annual WORLDSymposium(TM) read more